Prescription medicine

Carbinoxamine Brand names: Karbinal, Ryvent, Carbzah; first approved as Karbinal Er

Carbinoxamine (Ryvent) is a prescription medicine with an FDA approval on record since 2013. FDA's NDC Directory lists it from 7 generic labelers, and pharmacies paid $0.398 per carbinoxamine maleate 4 mg tablet in the October 7, 2026 NADAC survey.

Generic listed

Check it at the source: the carbinoxamine FDA label on DailyMed (effective March 6, 2024, Genus Lifesciences Inc.); the NDA 22556 record on Drugs@FDA; every carbinoxamine label on DailyMed.

Highlights of the record

FDA label of March 6, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026

Used for

From the label: indications and usage
Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis.

Forms and strengths

4 mg
6 mg
4 mg/5ml

Tablet; extended-release suspension; solution.

On the market

Earliest approval on file: March 28, 2013 Karbinal Er, Aytu; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: 10 first March 19, 2003; 5 with a marketed status in Drugs@FDA
Labelers listed (NDC): 9 of which 7 under generic applications, 1 under brand applications, repackagers included
Last listed patent: March 29, 2029 Karbinal ER oral suspension; not a generic launch date

Supply and safety

Pharmacy cost (NADAC): $0.398 per tablet Carbinoxamine maleate 4 mg tablet
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded
FAERS reports: 190 through July 30, 2026

What is carbinoxamine used for?

From the label: indications and usage
Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma.

Conditions named in the indications of carbinoxamine's FDA labels, with every medicine labeled for each:

Allergies

FDA pharmacologic class: Histamine-1 Receptor Antagonist.

Source: FDA drug label (Carbinoxamine Maleate), Genus Lifesciences Inc., effective March 6, 2024 (SPL set 9d11b197-cfdc-4b9b-9935-2920ccb6e522), via openFDA; the full label on DailyMed

Is there a generic for carbinoxamine (Ryvent)?

The FDA approved the first generic carbinoxamine on March 19, 2003. 10 generic applications are approved; 5 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.

FDA's NDC Directory lists carbinoxamine from 7 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.

The Orange Book lists 2 patents for Karbinal ER oral suspension, the last expiring on March 29, 2029. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

2013 earliest approval on file
2003 first generic approved
2029 last listed patent

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What do pharmacies pay for carbinoxamine (Ryvent)?

In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.398 per Carbinoxamine maleate 4 mg tablet, down 9% from $0.439 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.

Carbinoxamine maleate 4 mg tablet (generic)
Karbinal ER 4 mg/5 mL suspension (brand)

$1.20

$0.330

January 2024October 2026

NADAC per unit, October 7, 2026
Strength and form	Brand or generic	Pharmacy cost	30 tablets, or one pen or vial	12-month change
Carbinoxamine ER 4 mg/5 mL suspension	Generic	$1.05 per mL	n/a	-1%
Carbinoxamine maleate 4 mg tablet	Generic	$0.398 per tablet	$11.94	-9%
Karbinal ER 4 mg/5 mL suspension	Brand	$1.19 per mL	n/a	-0.1%

Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price

What do FAERS reports show for carbinoxamine?

The FDA Adverse Event Reporting System holds 190 reports that list carbinoxamine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 29 are coded as a death and 29 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

Drug Ineffective (a use or a product term, not a reaction)16
Drug Toxicity14
Headache (named in the label)14
Sinusitis10
Pain9
Pyrexia9
Fatigue (named in the label)8
Pruritus8

Side effects: the label's list and every FAERS reaction

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What else is labeled for the same conditions as carbinoxamine?

11 other medicines are given the same way (oral) and in the same FDA class as carbinoxamine or labeled mainly for the same use (allergies), the same class first. Allergies lists all 36 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

Medicine	Shared indication	Generic labelers (oral)	Pharmacy cost	Shortage
Diphenhydramine	Allergies	4 labelers	$0.0185 per mL 12.5 mg/5 mL	No current entry
Cetirizine	Allergies	164 labelers	$0.0613 per tablet 10 mg tablet	No current entry
Fexofenadine	Allergies	110 labelers	$0.230 per tablet 180 mg tablet	No current entry
Levocetirizine	Allergies	53 labelers	$0.0511 per tablet 5 mg tablet	No current entry
Chlorpheniramine	Allergies	2 labelers	$0.0177 per tablet 4 mg tablet	No current entry
Desloratadine	Allergies	9 labelers	$0.258 per tablet 5 mg tablet	No current entry
Chlorpheniramine and ibuprofen and phenylephrine	Allergies	none listed	n/a	No current entry
Chlorpheniramine and ibuprofen and pseudoephedrine	Allergies	none listed	n/a	No current entry

Every medicine labeled for the same conditions as carbinoxamine

Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)

What next?

Alternatives to carbinoxamine: 11 medicines for the same use
Other antihistamines: the pharmacologic class, with prices and generics
Carbinoxamine side effects: the label's list beside FAERS reports
Check an interaction: what two or more labels say about each other